
    
      Each eligible subject is treated with DAS181 for 10 days and observed for 28 days from the
      first day of administration.

      From day 1 to 10, once or twice a day, for 10 consecutive days, a total of 9 mg (7 ml)
      nebulized DAS181 is given. If DAS181 is given by twice a day, one vial containing 4.5 mg
      (3.5m1) DAS181 should be delivered with about 12-hour interval.
    
  